作者
Philippe Moreau,Alfred L. Garfall,Niels W.C.J. van de Donk,Hareth Nahi,Jesús F. San Miguel,Albert Oriol,Ajay K. Nooka,Thomas G. Martin,Laura Rosiñol,Ajai Chari,Lionel Karlin,Lotfi Benboubker,María‐Victoria Mateos,Nizar J. Bahlis,Rakesh Popat,Britta Besemer,Joaquín Martínez‐López,Surbhi Sidana,Michel Attal,Lixia Pei,Danielle Trancucci,Raluca Verona,Suzette Girgis,Shun Xin Wang Lin,Yunsi Olyslager,Mindy Jaffe,Clarissa Uhlar,Tara Stephenson,Rian Van Rampelbergh,Arnob Banerjee,Jeffrey L. Goldberg,Rachel Kobos,Amrita Krishnan,Saad Z. Usmani
摘要
Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma.
坚强的广山
eve
zho
rosalieshi
sswbzh
寻道图强
shinysparrow
薰硝壤
HEIKU
兔子
嗯哼
钱多多
saeda
Phosphene
yznfly
Gauss
Agee_Feng
狐少侠
丘比特
SciGPT
皖公网安备34019202002308
